FDA Brief

Warning letters Drugs

FDA warning letter to

Covalon Technologies Inc.

High riskIssued May 6, 2021Posted May 7, 2021Center for Drug Evaluation and Research

FDA warned Covalon Technologies that its CovaGuard non-alcohol hand sanitizers are unapproved drugs with COVID-19 and 24-hour protection claims.

What happened

FDA reviewed the company's website covaguard.com and its Instagram and Facebook pages on March 24, 2021. FDA found CovaGuard non-alcohol hand sanitizer products offered for sale in the United States with claims that they kill SARS-CoV-2 within 60 seconds and protect for 24 hours. FDA said the products are unapproved new drugs (drugs sold without FDA approval) and misbranded (labeling that violates drug law).

What FDA found

  1. Website and social media claims that the hand sanitizers kill SARS-CoV-2 and protect for 24 hours make them drugs intended to prevent or treat disease or affect the body.

    FD&C Act section 201(g)(1)(B)-(C), 21 U.S.C. 321(g)(1)(B)-(C)
  2. The hand sanitizers are unapproved new drugs because FDA has no approved application for them and they are not generally recognized as safe and effective for the claimed uses.

    FD&C Act section 505(a), 21 U.S.C. 355(a); section 301(d), 21 U.S.C. 331(d)
  3. The products are misbranded because they are nonprescription drugs under section 505G but do not meet that section's marketing requirements and have no approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)
  4. COVID-19 kill or prevention claims go beyond the general intended use allowed for topical antiseptics and do not conform to the 1994 tentative final monograph or later amendments.

    FD&C Act section 505G(a)(3), 21 U.S.C. 355h(a)(3); 1994 TFM as amended by 2016 proposed rule
  5. Claims of up to 24 hours of efficacy against serious pathogens, including SARS-CoV-2, do not conform to the applicable monograph and may create a false sense of security.

    FD&C Act section 505G(a)(3), 21 U.S.C. 355h(a)(3)
  6. The hand sanitizers do not fit FDA's temporary policy for alcohol-based hand sanitizer products during the public health emergency.

    FDA Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)

What FDA wants

Within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the specific steps taken to fix the violations and prevent recurrence, plus related documents. If complete action cannot be taken in 48 hours, state the reason and the time needed.

Who should pay attention

  • retailers and online marketplaces selling CovaGuard hand sanitizer
  • companies making COVID-19 or 24-hour protection claims for antiseptics
  • US importers and distributors of foreign hand sanitizer brands

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk